Oneview Healthcare PLC has launched a Security Purchase Plan (SPP) to raise up to A$2 million, following a recent A$19 million placement. The SPP offers eligible shareholders discounted shares to support AI development and customer deployments.
- SPP aims to raise approximately A$2 million at A$0.19 per share
- Offer follows a A$19 million two-tranche placement announced earlier in March
- Eligible securityholders can subscribe up to A$30,000 without brokerage fees
- Proceeds to strengthen balance sheet and advance AI-powered virtual assistant Ovie
- SPP is not underwritten and may be scaled back at company’s discretion
Context and Capital Raising
Oneview Healthcare PLC, a global healthcare technology company listed on the ASX, has commenced dispatch of its Security Purchase Plan (SPP) booklet, inviting eligible shareholders to participate in a capital raising initiative. This follows the company’s announcement on 16 March 2026 of a two-tranche placement raising A$19 million. The SPP aims to raise an additional A$2 million by offering new CHESS Depositary Interests (CDIs) at A$0.19 each, a 7% discount to the last closing price before the placement announcement.
The placement comprised a first tranche raising approximately A$12 million issued under existing ASX placement capacity, and a second tranche of about A$7 million to be issued to Oneview’s largest shareholder, Manderrah Pty Ltd, subject to shareholder approval expected in May 2026. The first tranche shares were issued on 25 March 2026, coinciding with the opening of the SPP.
Offer Details and Shareholder Participation
The SPP is open to eligible securityholders registered as of 7:00pm Sydney time on 13 March 2026, with addresses in Australia, New Zealand, or Ireland, excluding those in the United States or acting for US persons. Shareholders can apply for parcels ranging from A$1,000 up to a maximum of A$30,000 worth of new CDIs without incurring brokerage or transaction fees. The issue price matches the placement price at A$0.19 per CDI, representing a meaningful discount to recent market prices.
Importantly, the SPP is not underwritten, and Oneview reserves the right to scale back applications or increase the offer size at its discretion. This introduces some uncertainty around the final amount raised and allocation to shareholders. New CDIs issued under the SPP will rank equally with existing shares and are expected to commence trading on the ASX by 20 April 2026.
Use of Proceeds and Strategic Focus
Oneview intends to deploy the net proceeds to strengthen its balance sheet as it continues to convert its signed customer pipeline into live, revenue-generating deployments. A key focus is advancing its AI-powered virtual patient assistant, Ovie, alongside ongoing improvements in AI software development and automation initiatives aimed at driving operational efficiency. The company highlights that a strong balance sheet is increasingly critical in securing contracts with major US health systems, which remain a core market for Oneview’s growth.
Risks and Considerations
The company’s announcement includes a comprehensive risk disclosure covering strategic, operational, financial, and general market risks. These range from execution risks in scaling and product development, competition from established and emerging players, to technology and cybersecurity vulnerabilities. Notably, Oneview acknowledges the inherent risks in its AI initiatives, including potential unintended AI behaviour despite adherence to responsible AI development standards.
Investors are cautioned about market price volatility, dilution risks from the placement and SPP, and the non-underwritten nature of the SPP which may lead to scale-backs. The company also underscores the importance of consulting professional advisers before participating.
Looking Ahead
With the SPP offer period open until 10 April 2026, Oneview’s ability to successfully raise the targeted funds and execute on its growth and AI development plans will be closely watched. The pending shareholder approval for the second tranche of the placement adds another milestone to monitor in the coming months. As Oneview navigates competitive pressures and technological innovation in digital health, its capital raising efforts reflect a strategic push to solidify its market position and financial footing.
Bottom Line?
Oneview’s SPP launch marks a pivotal step in funding its AI ambitions and customer growth, but investor appetite and execution risks remain key to watch.
Questions in the middle?
- Will the SPP reach its A$2 million target or face significant scale-backs?
- How will shareholder approval for the second tranche to Manderrah Pty Ltd impact capital structure?
- Can Oneview’s AI initiatives, including Ovie, deliver competitive differentiation amid rising market competition?